Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Tolaney

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2024
Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopesP Tarantino, S M Tolaney
ESMO Open|October 12, 2025
Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational studyC Corti, S M Tolaney
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2024
Is adjuvant ribociclib ready for prime time?A Natarajan, S M Tolaney
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2023
Elacestrant: who are optimal candidates for the first oral SERD?M Lipsyc-Sharf, S M Tolaney
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2023
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatmentP Tarantino, S M Tolaney, G Curigliano
ESMO Open|December 14, 2024
Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancerK Fanucci, A Giordano, T Erick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 12, 2023
Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?A Giordano, N U Lin, S M Tolaney, et al.
ESMO Open|November 7, 2024
Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancerG Nader-Marta, A G Waks, S M Tolaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancerH Mamiya, R K Tahara, S M Tolaney, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 19, 2021
Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancersM F Tolba, H Elghazaly, E Bousoik, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2024
Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopesP Tarantino, S M Tolaney
ESMO Open|October 12, 2025
Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational studyC Corti, S M Tolaney
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2024
Is adjuvant ribociclib ready for prime time?A Natarajan, S M Tolaney
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2023
Elacestrant: who are optimal candidates for the first oral SERD?M Lipsyc-Sharf, S M Tolaney
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2023
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatmentP Tarantino, S M Tolaney, G Curigliano
ESMO Open|December 14, 2024
Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancerK Fanucci, A Giordano, T Erick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 12, 2023
Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?A Giordano, N U Lin, S M Tolaney, et al.
ESMO Open|November 7, 2024
Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancerG Nader-Marta, A G Waks, S M Tolaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancerH Mamiya, R K Tahara, S M Tolaney, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 19, 2021
Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancersM F Tolba, H Elghazaly, E Bousoik, et al.
Pageof 6